Revenue - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	May 31, 2023	Feb. 28, 2019	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			$ 43,190,000	$ 48,926,000	$ 85,063,000	$ 86,573,000
Deferred revenue			91,069,000		91,069,000		$ 93,423,000
Immune Medicine Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			1,800,000	17,500,000	6,400,000	26,700,000
Medicare Reimbursements
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement			1,500,000	1,300,000	2,800,000	2,700,000
Medicare Reimbursements | Immune Medicine Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement						400,000
Medicare Reimbursements | MRD Service Revenue
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement						$ 2,300,000
MRD Development Agreements | Maximum
Disaggregation Of Revenue [Line Items]
Additional milestone payment receivable			427,500,000		427,500,000
Genentech Collaboration Agreement
Disaggregation Of Revenue [Line Items]
Revenue from collaboration agreement				$ 7,700,000
Non-refundable upfront payments received		$ 300,000,000.0			300,000,000.0
Expected revenue through milestone payments			1,800,000,000		$ 1,800,000,000
Additional transaction price of regulatory milestone	$ 10,000,000
Genentech Collaboration Agreement | Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Additional transaction price of regulatory milestone	$ 10,000,000.0
Genentech Collaboration Agreement | Maximum
Disaggregation Of Revenue [Line Items]
Revenue recognition expected period					9 years
Genentech Collaboration Agreement | Maximum | Regulatory Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			65,000,000.0		$ 65,000,000.0
Genentech Collaboration Agreement | Maximum | Development Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			300,000,000.0		300,000,000.0
Genentech Collaboration Agreement | Maximum | Commercial Milestones
Disaggregation Of Revenue [Line Items]
Expected revenue through milestone payments			$ 1,430,000,000		$ 1,430,000,000